Dr Robert Jones - PhD
Jones RH, Moreno S, Nurse P and Jones N. Expression of the SV40 Promoter In Fission Yeast: Identification an Characterisation of an AP1-like Factor. (1988) Cell 53: p 659-667.
Jones RH and Jones NC Mammalian cAMP-responsive element can activate transcription in yeast and binds a yeast factor(s) that resembles the mammalian transcription factor ATF. (1999) Proc Natl Acad Sci USA. Vol 86; p 2176-2180
JB Millar, CH McGowan, G Lenaers, R Jones, and P Russell. p80cdc25 mitotic inducer is the tyrosine phosphatase that activates p34cdc2 kinase in fission yeast. (1990) EMBO J; 45: p 5610-5621
Jones RH and Twelves C. Oral uracil-tegafur: an alternative to intravenous 5-fluorouracil? (2001) Expert Opin. Pharmacother. 2 (9) 1513-1523
Jones RH and Vasey PA. New directions in testicular cancer; molecular determinants of oncogenesis and treatment success. European Journal of Cancer. 39(2):147-56, 2003
Jones R. Ryan M. Friedlander M. Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation. Gynecologic Oncology. 89(1):112-5, 2003
Jones R. Goldstein D. Kurtovic J. Keogh G. Riordan SM. Compression of liver parenchyma by a malignant hepatic cyst. American Journal of Gastroenterology. 98(5):1211-3, 2003
Jones RH and Vasey PA. The management of early testicular cancer. Lancet Oncology 4; 730-737,2003
Jones RH and Vasey PA. The management of advanced testicular cancer. Lancet Oncology 4; 738-747, 2003
Jones RH, Reubi JC, Millan D, and Vasey PA. Octreotide: an active agent in epithelial ovarian carcinoma?. Lancet Oncol (4):251-3, 2004
*H M R Robinson, *R Jones, M Walker, G Zachos, R Brown, J Cassidy and D A F Gillespie (*Joint first authorship). Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene 25, 5359–5369, 2006